Doxorubicin Market

Doxorubicin Market Analysis By Formulation (Lyophilized Doxorubicin Powder & Doxorubicin Solution), By Type (Breast Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer, Bladder Cancer, Stomach Cancer & Leukemia), By Distribution Channel & Region – Global Market Insights 2022-2026

Analysis of Doxorubicin market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Doxorubicin Market Outlook (2022-2026)

Demand for doxorubicin is anticipated to increase steadily at a CAGR of 5.3% from 2022 to 2026. At present, the global doxorubicin market stands at US$ 1.1 Billion, and are projected to reach a valuation of US$ 1.3 Billion by the end of 2026.

Shipments of doxorubicin in Japan and Canada are projected to increase at CAGRs of 3.9% and 5.3%, respectively, through 2026.

Report Attributes


Doxorubicin Market Size (2022)

US$ 1.1 Billion

Projected Year Value (2026F)

US$ 1.3 Billion

Global Market Growth Rate (2022-2026)

5.3% CAGR

United States Market Value (2022)

US$ 443.56 Million

Key Companies Profiled

  • Changzhou Kinyond Pharmaceutical Co. Ltd.
  • Cipla Limited
  • Hikma Thymoorgan Pharmazie GmbH
  • Pfizer Inc.
  • Reddy’s Laboratories Ltd.
  • Synbias Pharma AG
  • Janssen-Cilag Pty Limited
  • Meiji Seika Pharma Co. Ltd.
  • Accord Healthcare Ireland Ltd.
  • Cadila Healthcare Limited
  • MicroBiopharm Japan Co. Ltd.
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd.
  • TTY Biopharm Company Limited

As the incidence of cancer rises on a global level, so will the demand for chemotherapy medications that are used to treat it. Some of the widely used cancer medications are adriamycin, docetaxel, cyclophosphamide, cisplatin, and etoposide.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Will Rising Prevalence of Breast Cancer Drive Doxorubicin Demand?

“Rising Incidence of Breast Cancer Drives Demand for Several Chemotherapy Medications”

Increased awareness of breast cancer has resulted in a large number of diagnoses and hence also increased demand for treatment as well.

The use of Doxil for metastatic breast cancer and the use of Doxil for chemotherapy in breast cancer has increased in recent years and this trend will be prevalent across the forecast period as well which will subsequently drive doxorubicin shipments through 2026.

Doxorubicin market forecast by Fact.MR

Which Regional Market Will Lead Revenue Generation for Doxorubicin Manufacturers?

“North America to Account for Major Revenue Share in Global Market”

Increasing cancer cases and the rising use of doxorubicin for cancer treatment are the two prime factors that drive doxorubicin market potential in the region of North America. High research activity and increasing support from governments to increase awareness about cancer will also create a lucrative setting for doxorubicin vendors.

This region will lead the global doxorubicin market in terms of revenue share throughout the forecast period. The U.S. will be the major market in this region and Canada doxorubicin market is expected to evolve at a CAGR of 5.3% over the coming years.

The Europe doxorubicin market is expected to account for a significant market share by the end of 2026 and growth in this region will be driven by the rising geriatric population and increasing incidence of multiple cancer types like ovarian breast, colon, prostate, etc. Sales of doxorubicin in Germany are projected to rise at a CAGR of 4.3% over the next four years.

The market for doxorubicin in South Asia and East Asia is also anticipated to exhibit lucrative revenue opportunities for doxorubicin suppliers owing to increased focus on healthcare in these regions. Sales of doxorubicin in China are projected to reach US$ 106.6 Million while increasing at a CAGR of 7.5% from 2022 to 2026. Consumption of doxorubicin in Japan is anticipated to increase at a CAGR of 3.9% across the forecast period.

Country-wise Insights

Why Do Doxorubicin Suppliers Eye the U.S. Market?

“Adoption of Technologically-advanced Treatments & Developed Healthcare Infrastructure Provide Lucrative Opportunities for Doxorubicin Vendors”

The United States is the most lucrative market for doxorubicin on a global scale and this can be attributed to the increasing incidence of multiple cancers, the presence of developed healthcare infrastructure, and rising awareness of cancer treatments. Supportive government initiatives and rapid adoption of advanced treatments are also expected to provide lucrative opportunities for doxorubicin manufacturers.

Doxorubicin companies are focusing on launching new products in the nation to maximize their revenue generation potential and increase their market presence.

  • For instance, in September 2020, Zydus Cadila, a leading name in the doxorubicin market, announced that it had received final approval for the commercialization of its generic Doxorubicin Hydrochloride Liposome injection by the FDA (Food and Drug Administration), which is used for the treatment of cancers in the U.S.

Category-wise Insights

Which Type of Cancer Accounts for Most Demand for Doxorubicin?

“Ovarian Cancer Accounts for Highest Doxorubicin Consumption”

The world has witnessed a substantial increase in the incidence of ovarian cancer and this trend is anticipated to majorly influence doxorubicin sales across the world. Doxil for ovarian cancer treatment has gained massive popularity in recent years and is anticipated to follow a similar trend throughout the forecast period.

Liposomal Doxil and carboplatin for ovarian cancer are used as a combination treatment. The rising incidence of ovarian cancer will further drive demand for all chemotherapy medications that are crucial to the treatment of this disease.

How Did the COVID-19 Pandemic Influence Doxorubicin Sales?

In 2020, the sudden emergence of coronavirus infections spread through the world like rapid wildfire and created a pandemic situation that the world was not equipped to grapple with. In an attempt to contain the spread of infections multiple nations across the world implemented strict lockdowns that restricted outdoor activity and had a negative impact on the world economy.

These restrictions had a negative impact on the global doxorubicin market growth potential. The shift of focus in the healthcare industry led to a drop in sales of doxorubicin in this period. Other factors such as lack of healthcare resources to treat other diseases and restricted visits to healthcare institutions also led to a downfall in the consumption of doxorubicin.

Shipments of doxorubicin are anticipated to see a steady rise in the post-pandemic era as restrictions are lifted and the world returns to normal. Increasing incidence of cancer and rising demand for cancer medications will further boost market potential over the coming years.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Key Segments Covered in Doxorubicin Industry Research

  • By Formulation :

    • Lyophilized Doxorubicin Powder
    • Doxorubicin Solution
  • By Cancer Type :

    • Breast Cancer
    • Prostate Cancer
    • Ovarian Cancer
    • Lung Cancer
    • Bladder Cancer
    • Stomach Cancer
    • Leukemia
    • Other Types of Cancers
  • By Distribution Channel :

    • Hospital Pharmacies
    • Retail Pharmacies
    • e-Commerce
  • By Region :

    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • MEA

- FAQs -

By 2026, the global market for doxorubicin is anticipated to account for a revenue total of US$ 1.3 Billion.

Demand for doxorubicin is anticipated to expand at a CAGR 5.3% from 2022 to 2026.

The China doxorubicin market is projected to surge at a CAGR of 7.5% and attain a net value of US$ 106.6 Million by the end of 2026.

The U.S. doxorubicin market currently holds a prominent market share of around 40.5% and is valued at US$ 443.5 Million in 2022.

The global doxorubicin market stands at a valuation of US$ 1.1 Billion in 2022.

Key doxorubicin manufacturers such as Cadila Healthcare Limited, Changzhou Kinyond Pharmaceutical Co. Ltd., Cipla Limited, Hikma Thymoorgan Pharmazie GmbH, Janssen-Cilag Pty Limited, Meiji Seika Pharma Co. Ltd., MicroBiopharm Japan Co. Ltd., Novartis Inte

Doxorubicin Market

Schedule a Call

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Privacy Policy